Association between the Lipoprotein-Associated Phospholipase A2 Activity and the Progression of Subclinical Atherosclerosis

被引:1
|
作者
Liu, Jing [1 ]
Wang, Wei [1 ]
Qi, Yue [1 ]
Yong, Qiang [2 ]
Zhou, Guanghua [3 ]
Wang, Miao [1 ]
Sun, Jiayi [1 ]
Liu, Jun [1 ]
Jia, Zhangrong [1 ]
Zhao, Dong [1 ]
机构
[1] Capital Med Univ, Beijing Inst Heart Lung & Blood Vessel Dis, Beijing An Zhen Hosp,Dept Epidemiol, Key Lab Remodeling Related Cardiovasc Dis,Minist, Beijing 100029, Peoples R China
[2] Capital Med Univ, Dept Ultrasonog, Beijing An Zhen Hosp, Beijing 100029, Peoples R China
[3] Peking Univ Hosp, Dept Internal Med, Beijing, Peoples R China
基金
中国国家自然科学基金;
关键词
Lipoprotein-associated phospholipase A2; Atherosclerosis; Cohort study; ACTIVATING-FACTOR ACETYLHYDROLASE; C-REACTIVE PROTEIN; CORONARY-HEART-DISEASE; A(2) MASS; RISK-FACTOR; PREVENTION;
D O I
暂无
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Aim: The lipoprotein-associated phospholipase A2 (Lp-PLA(2)) level has been shown to be associated with the risk of clinical cardiovascular events. We aimed to investigate whether Lp-PLA(2) is associated with the progression of subclinical atherosclerosis in the general population. Methods: The degree of carotid plaque and the maximal intima-media thickness (IMT) were measured twice over a 5-year interval in 913 participants 45 to 74 years of age at baseline in a cohort study. The associations between the plasma Lp-PLA(2) activity and the progression of carotid plaque and changes in the IMT level were assessed according to sex after adjusting for traditional risk factors and the high-sensitivity C-reactive protein (hsCRP) level. Results: During the 5-year follow-up period, the progression of plaque was observed in 58.5% of men and 48.3% of women. The median maximal IMT level increased by 0.12 mm in men and 0.09 mm in women per year. The progression of plaque and changes in the IMT level increased according to the quartile of the Lp-PLA(2) activity in men (p<0.05 for trend), but not women. Following adjustment for traditional risk factors and the hsCRP level, the odds ratio for plaque progression associated with an increase in the Lp-PLA(2) activity of one standard deviation was 1.28 (95% CI=1.09-1.49, p=0.043) in men and 0.92 (95% CI=0.78-1.08, p=0.273) in women. The regression coefficient for IMT progression was 0.003 (p=0.004) in men and -0.001 (p=0.166) in women after adjusting for the other factors. Conclusions: The Lp-PLA(2) level is associated with the progression of subclinical atherosclerosis in men. Lp-PLA(2) may play an important role in the pathogenesis of atherosclerosis and be a potential target for the early prevention of cardiovascular disease.
引用
收藏
页码:532 / 542
页数:11
相关论文
共 50 条
  • [11] Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis
    Kolodgie, Frank D.
    Burke, Allen P.
    Skorija, Kristi S.
    Ladich, Elena
    Kutys, Robert
    Makuria, Addisalem Taye
    Virmani, Renu
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2006, 26 (11) : 2523 - 2529
  • [12] Lipoprotein-Associated Phospholipase A2 is Associated with Cardiovascular Mortality and Subclinical Atherosclerosis Phenotypes in African-Americans
    deLuna, Andres
    Brilakis, Emmanouil
    Ayers, Colby
    McGuire, Darren
    deLemos, James
    Khera, Amit
    CIRCULATION, 2012, 126 (21)
  • [13] Lipoprotein-associated phospholipase A2
    McConnell, Joseph P.
    Hoefner, Daniel M.
    CLINICS IN LABORATORY MEDICINE, 2006, 26 (03) : 679 - +
  • [14] Translational Studies of Lipoprotein-Associated Phospholipase A2 in Inflammation and Atherosclerosis
    Ferguson, Jane F.
    Hinkle, Christine C.
    Mehta, Nehal N.
    Bagheri, Roshanak
    DerOhannessian, Stephanie L.
    Shah, Rhia
    Mucksavage, Megan I.
    Bradfield, Jonathan P.
    Hakonarson, Hakon
    Wang, Xuexia
    Master, Stephen R.
    Rader, Daniel J.
    Li, Mingyao
    Reilly, Muredach P.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 59 (08) : 764 - 772
  • [15] Lipoprotein(a) and Vascular Inflammation: Association of Lipoprotein-associated Phospholipase A2 Activity With Lipoprotein(a) in African Americans
    Byambaa, Enkhmaa
    Erdembileg, Anuurad
    Zhang, Wei
    Berglund, Lars
    CIRCULATION, 2009, 120 (18) : S528 - S528
  • [16] Advantages of the lipoprotein-associated phospholipase A2 activity assay
    Donato, Leslie J.
    Meeusen, Jeffrey W.
    Callanan, Heidi
    Saenger, Amy K.
    Jaffe, Allan S.
    CLINICAL BIOCHEMISTRY, 2016, 49 (1-2) : 172 - 175
  • [17] Darapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, Reduces Rho Kinase Activity in Atherosclerosis
    Zhang, Juan
    Xu, Dong-Ling
    Liu, Xiao-Bo
    Bi, Shao-jie
    Zhao, Tong
    Sui, Shu-Jian
    Ji, Xiao-Ping
    Lu, Qing-Hua
    YONSEI MEDICAL JOURNAL, 2016, 57 (02) : 321 - 327
  • [18] Prediction of Lipoprotein-Associated Phospholipase A2 and Inflammatory Markers in Subclinical Atherosclerosis in Premature Ovarian Failure Patients
    Cekici, Yusuf
    Kilic, Salih
    Ovayolu, Ali
    Saracoglu, Erhan
    Duzen, Irfan Veysel
    Yilmaz, Mucahid
    Kaya, Bedri Caner
    Bozkurt, Devrim
    ACTA CARDIOLOGICA SINICA, 2021, 37 (01) : 30 - 37
  • [19] The association between uncarboxylated matrix Gla protein and lipoprotein-associated phospholipase A2
    Mayer, Otto, Jr.
    Seidlerova, Jitka
    Vaneka, Jiri
    Kielbergerova, Lenka
    Bruthans, Jan
    Filipovsky, Jan
    Wohlfahrt, Peter
    Cifkova, Renata
    Trefil, Ladislav
    Knapen, Marjo H. J.
    Drummer, Nadja E. A.
    Vermeer, Cees
    MATURITAS, 2015, 80 (01) : 82 - 88
  • [20] LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 AND STROKE
    Alvarez-Perez, F. J.
    Verde, I.
    REVISTA DE NEUROLOGIA, 2009, 49 (02) : 88 - 94